Digital health company, NeurodigitX reported on Wednesday the launch of Plastic Health platform, which allows a powerful mainstream bloodless assessment of inflammation levels in the current COVID-19 pandemic to enhance vaccine immunization strategies.
The company reportedly collects HRV, respiratory and cognitive data with the Plastic Egg, a biosensor and breathing-based game controller and Plastic mobile games guiding user's breath to measure inflammation accurately. Repeated gameplay allows profiling of slowly evolving (stress, chronic disease) and rapid changes (virus exposure, immunization) in inflammation status.
According to the company, it provides the only protocol-controlled, high-resolution, longitudinal, individualized routine measure of HRV and brain plasticity to closely track inflammation status. The Plastic Health reveals a draining of plasticity reserve, reflecting inflammation changes.
Nearly 50,000 scientific studies have been released on HRV (Heart Rate Variability), which affords a noninvasive assessment of inflammation of brain and bodily function. The company's Plastic Health combines individualized assessment and the heatmapping of public health. COVID-19 infection shows sudden inflammation change, further altered by the negative impact of cumulative stress.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
D3 Bio announces Series A+ Round completion to advance innovative oncology pipeline
Dizal's sunvozertinib receives US FDA Breakthrough Therapy Designation
Merck launches Phase 3 trial of MK-1084 and KEYTRUDA combination in metastatic NSCLC
Trevi Therapeutics names new vice president of Clinical Development
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Merck reports lung cancer trial failed to meet endpoints
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib